How semaglutide impacts HFpEF
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist […]
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist […]
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with […]
A new paper in the journal Function, published by Oxford Univetrsity Press, finds that a widely prescribed drug for treating hypertension, amlodipine, is not dangerous for patients, despite recent concerns from […]
The the latest data on universal screening for type 1 diabetes (T1D) is reveiwed in a session at this year’s Annual Meeting of the European Association for the […]
A new analysis reveals that rates of opioid prescribing to US adolescents have decreased in recent years, primarily limited to non-surgery indications. Opioid prescription rates for surgery have […]
Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up […]
HPV, or human papillomavirus, is the most common sexually transmitted infection. It is also the leading cause of cervical cancer. Over 1,400 Canadian women are affected yearly, with […]
UCLA-led research suggests that diabetes control can significantly improve for Latinos when a pharmacist implements an intervention that addresses these patients’ barriers to medication adherence. In this pharmacist-led […]
When PrEP (pre-exposure prophylaxis), a drug that prevents HIV infection, was first approved by the FDA in 2012, it was a medical breakthrough that promised to drastically reduce […]
The highest ever number of opioid-related overdose deaths in the United States was recorded in 2020 at 68,630, a 68% increase in just two years. Naloxone is a […]
Attention-deficit/hyperactivity disorder (ADHD) is among the most common pediatric neurodevelopmental disorders. In 2019, nearly 10% of United States (U.S.) children had a diagnosis of ADHD. Approximately 3.3 million […]
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents […]
ADVERTISMENT